Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Coverage Speech Therapy topic
No spam. Unsubscribe anytime.
Committee advances bill to require insurance coverage for stuttering treatment after emotional testimony
Summary
The Senate Commerce Committee released S-3502 after testimony from clinicians, researchers and residents describing stuttering as a persistent neurodevelopmental disorder and urging coverage that emphasizes functional outcomes rather than fluency alone.
The Senate Commerce Committee voted to release S-3502, which would require health insurers and the state Medicaid program to cover treatment for stuttering, including habilitative and rehabilitative speech therapy, and to limit the use of prior authorization or other utilization management that blocks access to care.
Speakers included people who stutter and clinicians. Emily Root, a speech-language pathologist who teaches a stuttering course at Kean University, told the panel that roughly 1% of people persistently stutter and that in New Jersey that number equates to about 95,000 residents, including an estimated 20,000 children. Root said effective treatment focuses on participation, reduced avoidance and improved quality of life — outcomes she urged insurers to recognize rather than measuring progress by mere fluency.
Jim Contreras, a speech-language pathologist, researcher and person who stutters, said stuttering is a complex neurodevelopmental disorder that often requires long-term, individualized treatment. Contreras warned that typical insurance utilization-management rules — short authorization cycles and arbitrary session limits — are designed for acute conditions and do not fit stuttering therapy, which can produce nonlinear and long-term progress.
Michael Kidd Gilchrist and Benjie, a 13-year-old student who stutters, gave personal testimony about social, educational and vocational impacts. Benjie told the committee he receives private and school-based therapy and urged coverage expansion so others can access treatment.
Senators pressed witnesses on coverage details and the proposed committee amendment to align prior-authorization rules with the state's Ensuring Transparency and Prior Authorization Act. After discussion, the committee amended and released S-3502 for further consideration.
Next steps include possible technical work on how prior authorization and outcome measurement will be defined in final bill language.
